484 related articles for article (PubMed ID: 26282467)
1. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa.
Kelly G; Hughes R; McGarry T; van den Born M; Adamzik K; Fitzgerald R; Lawlor C; Tobin AM; Sweeney CM; Kirby B
Br J Dermatol; 2015 Dec; 173(6):1431-9. PubMed ID: 26282467
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.
van der Zee HH; de Ruiter L; van den Broecke DG; Dik WA; Laman JD; Prens EP
Br J Dermatol; 2011 Jun; 164(6):1292-8. PubMed ID: 21332464
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
4. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression.
Navrazhina K; Garcet S; Zheng X; Hur HB; Frew JW; Krueger JG
J Allergy Clin Immunol; 2022 Jan; 149(1):135-144.e12. PubMed ID: 34081946
[TBL] [Abstract][Full Text] [Related]
5. Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy.
Moran B; Sweeney CM; Hughes R; Malara A; Kirthi S; Tobin AM; Kirby B; Fletcher JM
J Invest Dermatol; 2017 Nov; 137(11):2389-2395. PubMed ID: 28652108
[TBL] [Abstract][Full Text] [Related]
6. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa.
Thomi R; Yerly D; Yawalkar N; Simon D; Schlapbach C; Hunger RE
Br J Dermatol; 2017 Nov; 177(5):1358-1366. PubMed ID: 28301691
[TBL] [Abstract][Full Text] [Related]
8. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa.
Lima AL; Karl I; Giner T; Poppe H; Schmidt M; Presser D; Goebeler M; Bauer B
Br J Dermatol; 2016 Mar; 174(3):514-21. PubMed ID: 26436522
[TBL] [Abstract][Full Text] [Related]
9. Matrix remodelling and MMP expression/activation are associated with hidradenitis suppurativa skin inflammation.
Sanchez J; Le Jan S; Muller C; François C; Renard Y; Durlach A; Bernard P; Reguiai Z; Antonicelli F
Exp Dermatol; 2019 May; 28(5):593-600. PubMed ID: 30903721
[TBL] [Abstract][Full Text] [Related]
10. Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa.
Saraç Öztürk G; Ergun T; Peker Eyüboğlu İ; Akkiprik M
Cytokine; 2021 Aug; 144():155585. PubMed ID: 34034145
[TBL] [Abstract][Full Text] [Related]
11. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa.
Schlapbach C; Hänni T; Yawalkar N; Hunger RE
J Am Acad Dermatol; 2011 Oct; 65(4):790-798. PubMed ID: 21641076
[TBL] [Abstract][Full Text] [Related]
12. Bacterial biofilm is associated with higher levels of regulatory T cells in unaffected hidradenitis suppurativa skin.
Kjaersgaard Andersen R; Ring HC; Kallenbach K; Eriksen JO; Jemec GBE
Exp Dermatol; 2019 Mar; 28(3):312-316. PubMed ID: 30657613
[TBL] [Abstract][Full Text] [Related]
13. Inflammation induced changes in the expression levels of components of the microRNA maturation machinery Drosha, Dicer, Drosha co-factor DGRC8 and Exportin-5 in inflammatory lesions of hidradenitis suppurativa patients.
Hessam S; Sand M; Skrygan M; Gambichler T; Bechara FG
J Dermatol Sci; 2016 Jun; 82(3):166-74. PubMed ID: 26917346
[TBL] [Abstract][Full Text] [Related]
14. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway.
Cho KA; Suh JW; Lee KH; Kang JL; Woo SY
Int Immunol; 2012 Mar; 24(3):147-58. PubMed ID: 22207130
[TBL] [Abstract][Full Text] [Related]
15. Expression of miRNA-155, miRNA-223, miRNA-31, miRNA-21, miRNA-125b, and miRNA-146a in the Inflammatory Pathway of Hidradenitis Suppurativa.
Hessam S; Sand M; Skrygan M; Gambichler T; Bechara FG
Inflammation; 2017 Apr; 40(2):464-472. PubMed ID: 28028756
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop.
Hessam S; Sand M; Gambichler T; Skrygan M; Rüddel I; Bechara FG
Br J Dermatol; 2018 Mar; 178(3):761-767. PubMed ID: 28975626
[TBL] [Abstract][Full Text] [Related]
17. The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.
Shah A; Alhusayen R; Amini-Nik S
Inflamm Res; 2017 Nov; 66(11):931-945. PubMed ID: 28656364
[TBL] [Abstract][Full Text] [Related]
18. Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies.
Schell SL; Cong Z; Sennett ML; Gettle SL; Longenecker AL; Goldberg SR; Kirby JS; Helm MF; Nelson AM
Br J Dermatol; 2023 Feb; 188(3):407-419. PubMed ID: 36680309
[TBL] [Abstract][Full Text] [Related]
19. Primary alterations during the development of hidradenitis suppurativa.
Dajnoki Z; Somogyi O; Medgyesi B; Jenei A; Szabó L; Gáspár K; Hendrik Z; Gergely P; Imre D; Póliska S; Törőcsik D; Zouboulis CC; Prens EP; Kapitány A; Szegedi A
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):462-471. PubMed ID: 34724272
[TBL] [Abstract][Full Text] [Related]
20. The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction.
Witte-Händel E; Wolk K; Tsaousi A; Irmer ML; Mößner R; Shomroni O; Lingner T; Witte K; Kunkel D; Salinas G; Jodl S; Schmidt N; Sterry W; Volk HD; Giamarellos-Bourboulis EJ; Pokrywka A; Döcke WD; Schneider-Burrus S; Sabat R
J Invest Dermatol; 2019 Jun; 139(6):1294-1305. PubMed ID: 30528824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
